PMLT21055 / APEC1621D / Mullen
Research Question:
Does the drug LY3023414 help patients with cancers that have spread to other places
in the body and do not respond to treatment?
Basic Study Information
Purpose:
This phase II Pediatric MATCH trial studies how well samotolisib works in treating
patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC
or PI3K/MTOR mutations that have spread to other places in the body (metastatic) and
have come back (recurrent) or do not respond to treatment (refractory). Samotolisib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Craig Mullen
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search